Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2020 16:05 ET | Source: Translate Bio, Inc.

Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference

-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
October 31, 2019 12:15 ET | Source: Translate Bio, Inc.

Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference

NASHVILLE, Tenn., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
October 01, 2019 07:30 ET | Source: Translate Bio, Inc.

Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
October 22, 2018 08:00 ET | Source: Celtaxsys, Inc.

Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference

ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
October 11, 2018 08:00 ET | Source: Celtaxsys, Inc.

Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference

ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
October 24, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
October 27, 2016 07:00 ET | Source: ProQR Therapeutics

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential...
September 27, 2016 07:00 ET | Source: ProQR Therapeutics

ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for...
September 22, 2016 07:30 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
October 01, 2015 08:03 ET | Source: Celtaxsys Inc.

Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients

ATLANTA, GA--(Marketwired - October 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today...